List of Excipients in Branded Drug FLUZONE HIGH-DOSE QUADRIVALENT NORTHERN HEMISPHERE

« Back to Dashboard

Fluzone High-Dose Quadrivalent Northern Hemisphere: Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Fluzone High-Dose Quadrivalent Northern Hemisphere was an egg-based, adjuvant-free influenza vaccine developed by Sanofi Pasteur for adults age 65 and older. Its commercial strategy relied on a 240-microgram total hemagglutinin dose, four influenza strains, a single-dose presentation, and a limited excipient profile designed for tolerability and manufacturing consistency. The principal opportunities around the product are not conventional generic substitution or excipient patent licensing. They are concentrated in high-dose antigen delivery, surfactant substitution, stability improvement, syringe systems, contract manufacturing, and next-generation influenza platforms.

The product is part of Sanofi's Fluzone franchise. Seasonal influenza products are updated as circulating strains change. Following the World Health Organization's recommendation to move from quadrivalent to trivalent seasonal influenza vaccines for the 2024-2025 season, Sanofi transitioned its U.S. high-dose product to a trivalent formulation marketed as Fluzone High-Dose.

What is Fluzone High-Dose Quadrivalent Northern Hemisphere?

Fluzone High-Dose Quadrivalent was a four-strain, high-antigen influenza vaccine for adults 65 years of age and older.

Attribute	Product detail
Manufacturer	Sanofi Pasteur Inc.
Active biological material	Inactivated influenza virus hemagglutinin
Vaccine type	Split-virion, inactivated influenza vaccine
Strains	Two influenza A strains and two influenza B strains
Antigen content	60 micrograms hemagglutinin per strain; 240 micrograms total per 0.7 mL dose
Adjuvant	None
Preservative	None in the single-dose presentation
Administration	Intramuscular injection
Target population	Adults 65 years and older
Regulatory category	Biologic vaccine regulated by FDA's Center for Biologics Evaluation and Research
Geographic scope	Northern Hemisphere seasonal formulation
Current status	Quadrivalent version was a prior seasonal formulation; U.S. high-dose product transitioned to trivalent composition for the 2024-2025 season

The high-dose design increases antigen quantity rather than using an adjuvant. FDA approved Fluzone High-Dose in 2009 and later approved Fluzone High-Dose Quadrivalent for adults 65 and older. The higher antigen load was intended to address reduced immune responsiveness in older adults. [1,2]

What excipients are used in Fluzone High-Dose Quadrivalent?

The formulation uses a short excipient list consisting principally of phosphate buffers and sodium chloride. The product does not depend on a proprietary oil-in-water adjuvant system.

Core formulation excipients

The Fluzone High-Dose Quadrivalent presentation contains:

• Sodium chloride
• Sodium phosphate monobasic
• Sodium phosphate dibasic
• Water for injection
• Residual manufacturing-related substances, including potential trace amounts of formaldehyde, octylphenol ethoxylate, hydrocortisone, and ovalbumin

The exact residual quantities can vary by manufacturing lot and are controlled under the approved manufacturing process. The vaccine is produced using embryonated chicken eggs, which creates a potential for residual egg protein. [1]

The product's prefilled syringe presentation is designed without thimerosal as a preservative. The syringe components are not made with natural rubber latex, according to the prescribing information. [1]

Why the excipient profile matters commercially

The excipient strategy supports four commercial objectives:

1. Reduce tolerability concerns in an older population.
2. Avoid the regulatory and supply-chain complexity associated with a new adjuvant.
3. Preserve compatibility with established influenza manufacturing processes.
4. Permit a ready-to-use, single-dose presentation for pharmacy, physician-office, and mass-vaccination channels.

The formulation does not attempt to solve immunogenicity through novel excipient chemistry. It uses a higher antigen dose and a conventional buffered aqueous vehicle.

How does the high-dose formulation compare with competing influenza vaccines?

Fluzone High-Dose Quadrivalent competed primarily against standard-dose vaccines and adjuvanted vaccines for older adults.

Product category	Antigen or adjuvant strategy	Primary differentiation
Fluzone High-Dose Quadrivalent	240 micrograms total hemagglutinin	High antigen content
Fluzone High-Dose trivalent	180 micrograms total hemagglutinin	Current high-dose seasonal strategy after quadrivalent-to-trivalent transition
Standard-dose quadrivalent vaccines	Approximately 60 micrograms total hemagglutinin	Conventional antigen quantity
Fluad Quadrivalent	Standard antigen content plus MF59 adjuvant	Immune stimulation through adjuvant
Flublok Quadrivalent	Recombinant hemagglutinin, higher antigen quantity, non-egg production	Recombinant manufacturing and high antigen content
Cell-based influenza vaccines	Cell-derived virus production	Reduced reliance on egg propagation

The central competitive comparison is high antigen dose versus adjuvantation. Fluzone High-Dose has a relatively simple excipient profile, while Fluad relies on the MF59 adjuvant system. Flublok differentiates through recombinant production and avoids egg-based virus propagation. The commercial value of each approach depends on clinical positioning, procurement contracts, manufacturing yield, supply reliability, and physician and payer preference. [3,4]

What excipient and formulation opportunities exist around Fluzone High-Dose?

The strongest opportunities are incremental rather than disruptive. A replacement excipient must preserve antigen integrity, maintain hemagglutinin potency, remain compatible with egg-derived split-virus material, and fit an established regulatory package.

Surfactant replacement

Octylphenol ethoxylate, commonly associated with Triton X-100-type processing chemistry, is used in influenza vaccine manufacturing and may occur as a residual. A supplier or platform technology that reduces or replaces this surfactant could offer:

• Lower residual process impurity exposure
• Simplified environmental and occupational controls
• Better alignment with sustainability requirements
• Potentially improved regulatory positioning in jurisdictions with tighter scrutiny of nonionic surfactants

The commercial barrier is validation. A replacement must demonstrate equivalent virus disruption, antigen recovery, purity, potency, and stability. This is more difficult than substituting a routine inactive ingredient in a small-molecule tablet.

Buffer optimization

The sodium phosphate system controls pH during storage and administration. Opportunities include:

• Improved pH control across seasonal strain updates
• Reduced aggregation of hemagglutinin
• Better compatibility with prefilled syringe materials
• Lower visible and subvisible particle formation
• Improved stability during refrigerated distribution

A buffer change may appear technically minor, but it can trigger comparability work because influenza antigens are strain-specific and the product is manufactured annually.

Protein and aggregation stabilization

High-dose vaccines contain four times the standard antigen quantity per strain relative to conventional-dose products. Increased antigen concentration can increase the risk of aggregation, adsorption to container surfaces, and potency loss.

Commercially relevant technologies include:

• Low-binding syringe materials
• Surface treatments for glass or polymer containers
• Stabilizing sugars or amino acids
• Improved freeze-thaw protection
• Reduced agitation sensitivity
• Enhanced control of particulate formation

Any new stabilizer would need to avoid compromising vaccine potency, sterility, syringe performance, and administration characteristics.

Prefilled syringe and device improvements

The single-dose prefilled syringe is part of the product's commercial proposition. Device opportunities include:

• Lower dead-volume syringes
• More reliable dose delivery
• Needle-safety integration
• Improved cold-chain robustness
• Automated inspection for particles and fill volume
• Packaging that reduces breakage and temperature excursions

Device and container patents may provide more practical protection than excipient patents because the delivery system is directly connected to manufacturing and administration workflows.

What patents protect Fluzone High-Dose Quadrivalent?

Fluzone High-Dose Quadrivalent is a biologic vaccine, not a conventional small-molecule prescription product. It is therefore not analyzed through the same Orange Book framework used for most small-molecule medicines.

The relevant protection layers are likely to include:

• Manufacturing processes for egg-derived influenza virus
• Strain selection and reassortment methods
• Virus splitting and purification
• Antigen concentration and potency control
• Formulation and stability
• Prefilled syringe and container systems
• Quality-control and release testing
• Trade secrets covering process parameters and scale-up

Public product-specific patent conclusions require a claim-by-claim review of U.S. Patent and Trademark Office records and Sanofi's patent families. The FDA prescribing information does not identify a single patent that defines the entire Fluzone High-Dose Quadrivalent product. [1]

Is Fluzone High-Dose Quadrivalent listed in the Orange Book?

No. The Orange Book is principally used for approved small-molecule drug products and their listed patents and exclusivity. Biologic vaccines licensed under a biologics license application are generally evaluated through the Public Health Service Act framework, including the Purple Book for biosimilar and interchangeable biological products. [5]

Does Fluzone High-Dose Quadrivalent have biosimilar risk?

Biosimilar risk is low in practical commercial terms. Seasonal influenza vaccines are updated by strain, manufactured through complex biological processes, and subject to annual regulatory changes. A competing manufacturer would ordinarily pursue its own vaccine license and seasonal manufacturing program rather than rely on an automatic biosimilar substitution pathway.

The more realistic threat is product-level competition from:

• Standard-dose influenza vaccines
• Adjuvanted vaccines for older adults
• Recombinant vaccines
• Cell-based vaccines
• Other high-dose formulations
• Government or health-system procurement alternatives

When did Fluzone High-Dose Quadrivalent lose exclusivity?

Fluzone High-Dose Quadrivalent does not have a single, readily determinative exclusivity expiration date comparable to a small-molecule product with one composition-of-matter patent.

Its commercial exclusivity is shaped by:

• FDA licensure and annual strain updates
• Manufacturing capacity
• Clinical positioning in adults 65 and older
• Supply contracts
• Product-specific process know-how
• Regulatory barriers to competing vaccines
• Any enforceable patents covering formulation, manufacturing, or devices

The 2024-2025 transition from quadrivalent to trivalent influenza vaccines reduced the commercial relevance of the Northern Hemisphere quadrivalent formulation. This transition resulted from public-health strain-selection policy rather than a patent expiration event. [6]

What is the FDA regulatory status of the product?

FDA approved Fluzone High-Dose Quadrivalent as a seasonal influenza vaccine for adults 65 and older. The product was supported by clinical and manufacturing data showing that the quadrivalent formulation met the applicable immunogenicity and safety requirements for the intended population. [2]

Seasonal influenza products are subject to recurring regulatory work because the antigenic composition changes. This creates continuing opportunities for regulatory and manufacturing service providers in:

• Strain update testing
• Potency assays
• Comparability protocols
• Stability studies
• Lot-release testing
• Process validation
• Cold-chain qualification

The need for annual updates limits the value of a static formulation patent. It increases the value of scalable production, rapid strain changeover, and validated analytical methods.

Which companies challenge Fluzone High-Dose commercially?

The most relevant competitors are Sanofi's own products and other manufacturers with vaccines for older adults.

Company	Product or platform	Competitive basis
CSL Seqirus	Fluad and other influenza vaccines	MF59 adjuvant and broad seasonal portfolio
AstraZeneca	FluMist	Live attenuated intranasal delivery
Dynavax	Next-generation adjuvanted vaccine collaborations and technologies	Immune stimulation platforms
Protein Sciences/Sanofi	Flublok	Recombinant hemagglutinin platform
GSK	Seasonal influenza products in selected markets	Global vaccine distribution and procurement access
Various regional manufacturers	Egg-based and cell-based influenza vaccines	Local supply, price, and government tenders

Competition is primarily commercial and regulatory, not Paragraph IV litigation. Paragraph IV certification applies to patents listed for eligible small-molecule products. It is not the normal route for challenging a biologic influenza vaccine license.

What licensing and partnership opportunities exist?

Potential licensing targets include:

• Low-residual or surfactant-free virus-splitting technologies
• High-concentration hemagglutinin stabilization
• Prefilled syringe systems
• Polymer or glass surface treatments
• Rapid seasonal strain replacement platforms
• Cell-based or recombinant manufacturing technology
• Analytical methods for antigen potency and aggregation
• Regional fill-finish and cold-chain capacity

Sanofi's scale makes technology licensing more likely to focus on manufacturing efficiency, supply resilience, or product differentiation than on a basic buffer substitution. A technology provider would need to show measurable value in yield, stability, quality, cost, or regulatory execution.

What generic launch risks exist for Fluzone High-Dose Quadrivalent?

A conventional generic launch model is not applicable. The principal launch risks for a competing high-dose influenza vaccine are:

• Failure to match seasonal strain requirements
• Inadequate manufacturing capacity
• Delayed lot release
• Insufficient clinical differentiation
• Weak distribution into pharmacies and Medicare channels
• Cold-chain failures
• Container-closure or syringe compatibility problems
• Difficulty demonstrating consistent potency across annual updates
• Procurement pressure from public and private payers

A competitor with a lower-cost formulation may still fail to gain share if it cannot supply product before the seasonal vaccination window.

How strong is the Fluzone High-Dose patent estate?

The product's practical protection is stronger in manufacturing know-how and regulatory execution than in a single foundational excipient patent. High-dose influenza vaccine production involves strain-specific biological material, egg propagation, purification, splitting, concentration, filling, and release testing. These steps create process complexity that can delay competition even when broad patent barriers are limited.

Patent strength should be assessed across five categories:

Category	Strategic value
Composition patents	Potentially narrow if limited to specific excipient combinations
Manufacturing patents	Important where they improve yield, purity, or antigen recovery
Formulation patents	Relevant to stability and high antigen concentration
Device patents	Relevant to prefilled syringes and dose delivery
Trade secrets	Often critical for scale-up and seasonal execution

A definitive freedom-to-operate conclusion requires a current patent-family and claim-status review in each target jurisdiction.

What commercial opportunities remain after the quadrivalent transition?

The highest-value opportunity is the broader high-dose influenza platform, not the discontinued or superseded quadrivalent label.

Commercial priorities include:

1. High-dose trivalent formulation optimization.
2. More stable concentrated antigen formulations.
3. Reduced-residual manufacturing processes.
4. Lower-cost prefilled syringe systems.
5. Regional fill-finish partnerships.
6. Cell-based and recombinant alternatives.
7. Combination respiratory vaccines for older adults.
8. Analytical platforms that accelerate annual strain updates.

Sanofi's vaccine business generated approximately EUR 7.5 billion in sales in 2023, although public reporting does not separately disclose Fluzone High-Dose Quadrivalent revenue. [7] Revenue exposure is therefore best assessed through Sanofi's broader influenza franchise, U.S. older-adult vaccination volumes, seasonal procurement, and the share captured by high-dose products.

Key Takeaways

• Fluzone High-Dose Quadrivalent used a simple, adjuvant-free phosphate-buffered formulation with 240 micrograms of total hemagglutinin per dose.
• Its main differentiation was high antigen quantity for adults 65 and older, not novel excipient chemistry.
• The product relied on egg-based manufacturing and could contain residual ovalbumin, formaldehyde, octylphenol ethoxylate, and hydrocortisone.
• The quadrivalent Northern Hemisphere formulation became commercially less relevant after the 2024-2025 transition to trivalent seasonal vaccines.
• Orange Book and Paragraph IV strategies are generally not applicable.
• Biosimilar substitution risk is low; competition from other licensed influenza vaccines is the principal threat.
• The most attractive licensing opportunities involve surfactant reduction, antigen stabilization, syringe systems, analytical methods, and manufacturing efficiency.
• Practical exclusivity is supported by regulatory complexity, manufacturing know-how, seasonal supply execution, and distribution rather than one clearly dominant product patent.

FAQs About Fluzone High-Dose Quadrivalent

Is Fluzone High-Dose Quadrivalent adjuvanted?

No. Its strategy is based on increased hemagglutinin antigen content rather than an MF59-type or other adjuvant.

Does Fluzone High-Dose Quadrivalent contain thimerosal?

The single-dose prefilled syringe presentation does not use thimerosal as a preservative.

Is Fluzone High-Dose Quadrivalent egg-free?

No. It is manufactured using embryonated chicken eggs and may contain residual ovalbumin.

Can a pharmacy substitute another high-dose influenza vaccine automatically?

Substitution depends on applicable FDA labeling, state pharmacy law, payer rules, and the specific vaccine presentation. High-dose, adjuvanted, recombinant, and standard-dose vaccines are not interchangeable solely because they target the same age group.

What is the main technical barrier to a competing high-dose influenza vaccine?

The main barrier is consistent seasonal manufacturing at scale. A competitor must control antigen yield, purity, potency, aggregation, sterility, filling, cold-chain performance, and annual strain updates.

References

1. Sanofi Pasteur Inc. (2023). Fluzone High-Dose Quadrivalent prescribing information. U.S. Food and Drug Administration. https://www.fda.gov
2. U.S. Food and Drug Administration. (2019). FDA approves new seasonal influenza vaccine for adults 65 years and older: Fluzone High-Dose Quadrivalent. https://www.fda.gov
3. Centers for Disease Control and Prevention. (2023). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices. https://www.cdc.gov/flu
4. U.S. Food and Drug Administration. (2023). Influenza vaccine products and regulatory information. https://www.fda.gov
5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
6. World Health Organization. (2024). Recommended composition of influenza virus vaccines for use in the 2024-2025 Northern Hemisphere influenza season. https://www.who.int
7. Sanofi. (2024). 2023 Universal Registration Document and annual financial report. https://www.sanofi.com